Cited 0 times in 
Cited 0 times in 
Effectiveness and Safety of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Yeon-Sook | - |
| dc.contributor.author | Choi, Jun Yong | - |
| dc.contributor.author | Park, Dae Won | - |
| dc.contributor.author | Kim, Shin-Woo | - |
| dc.contributor.author | Kim, Tae Hyong | - |
| dc.contributor.author | Ryu, Julie | - |
| dc.contributor.author | Harrison, Rebecca | - |
| dc.contributor.author | Lee, Jeong-a | - |
| dc.contributor.author | Park, Flora | - |
| dc.contributor.author | Lee, Sun Hee | - |
| dc.date.accessioned | 2025-12-02T06:33:47Z | - |
| dc.date.available | 2025-12-02T06:33:47Z | - |
| dc.date.created | 2025-11-21 | - |
| dc.date.issued | 2025-09 | - |
| dc.identifier.issn | 2093-2340 | - |
| dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/209244 | - |
| dc.description.abstract | BICtegravir Single Tablet Regimen is a multi-national observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with human immunodeficiency virus. We present 24-month data from participants in Korea. Eighty-eight participants (36 treatment-naive [TN], 52 treatment-experienced [TE]) were included. At 24 months, 100% (29/29) of TN and 100% (37/37) of TE participants had HIV-1 RNA <50 copies/mL (missing=excluded analysis). BIC/FTC/TAF persistence was 100% (33/33) and 96.1% (49/51) in TN and TE participants, respectively. Drug-related adverse events occurred in 2 TN participants. Improvements in some patient-reported outcomes were observed. BIC/FTC/TAF maintained effectiveness, | - |
| dc.description.statementOfResponsibility | open | - |
| dc.language | Korean, English | - |
| dc.publisher | 대한감염학회 | - |
| dc.relation.isPartOf | INFECTION AND CHEMOTHERAPY | - |
| dc.relation.isPartOf | INFECTION AND CHEMOTHERAPY | - |
| dc.rights | CC BY-NC-ND 2.0 KR | - |
| dc.title | Effectiveness and Safety of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR | - |
| dc.type | Article | - |
| dc.contributor.college | College of Medicine (의과대학) | - |
| dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
| dc.contributor.googleauthor | Kim, Yeon-Sook | - |
| dc.contributor.googleauthor | Choi, Jun Yong | - |
| dc.contributor.googleauthor | Park, Dae Won | - |
| dc.contributor.googleauthor | Kim, Shin-Woo | - |
| dc.contributor.googleauthor | Kim, Tae Hyong | - |
| dc.contributor.googleauthor | Ryu, Julie | - |
| dc.contributor.googleauthor | Harrison, Rebecca | - |
| dc.contributor.googleauthor | Lee, Jeong-a | - |
| dc.contributor.googleauthor | Park, Flora | - |
| dc.contributor.googleauthor | Lee, Sun Hee | - |
| dc.identifier.doi | 10.3947/ic.2025.0061 | - |
| dc.relation.journalcode | J01053 | - |
| dc.identifier.eissn | 2092-6448 | - |
| dc.identifier.pmid | 40958487 | - |
| dc.subject.keyword | Combination antiretroviral therapy | - |
| dc.subject.keyword | Korea | - |
| dc.subject.keyword | Asia | - |
| dc.subject.keyword | bictegravir | - |
| dc.subject.keyword | observational study | - |
| dc.contributor.alternativeName | Choi, Jun Yong | - |
| dc.contributor.affiliatedAuthor | Choi, Jun Yong | - |
| dc.identifier.scopusid | 2-s2.0-105017296338 | - |
| dc.identifier.wosid | 001586896700012 | - |
| dc.citation.volume | 57 | - |
| dc.citation.number | 3 | - |
| dc.citation.startPage | 424 | - |
| dc.citation.endPage | 430 | - |
| dc.identifier.bibliographicCitation | INFECTION AND CHEMOTHERAPY, Vol.57(3) : 424-430, 2025-09 | - |
| dc.identifier.rimsid | 90165 | - |
| dc.type.rims | ART | - |
| dc.description.journalClass | 1 | - |
| dc.description.journalClass | 1 | - |
| dc.subject.keywordAuthor | Combination antiretroviral therapy | - |
| dc.subject.keywordAuthor | Korea | - |
| dc.subject.keywordAuthor | Asia | - |
| dc.subject.keywordAuthor | bictegravir | - |
| dc.subject.keywordAuthor | observational study | - |
| dc.subject.keywordPlus | ANTIRETROVIRAL THERAPY | - |
| dc.subject.keywordPlus | TENOFOVIR ALAFENAMIDE | - |
| dc.subject.keywordPlus | MULTICENTER | - |
| dc.subject.keywordPlus | PHASE-3 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART003251004 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
| dc.relation.journalResearchArea | Infectious Diseases | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.